Table 3 ILD incidence rate per 1000 PY, unadjusted
Cohort | Specific definition | Sensitive definition |
|---|---|---|
Events (total PY) | Events (total PY) | |
Rate (95 % CI) | Rate (95 % CI) | |
All eligible | 16 (9107) | 59 (9154) |
1.8 (1.0–2.9) | 6.4 (4.9–8.3) | |
Anti-TNFα agents | 9 (5473) | 39 (5527) |
1.6 (0.8–3.1) | 7.1 (5.0–9.6) | |
Etanercept | 0 (1012) | 6 (1015) |
0.0 (0.0–3.0) | 5.9 (2.2-12.9) | |
Adalimumab | 3 (1674) | 12 (1692) |
1.8 (0.4-5.2) | 7.1 (3.7–12.4) | |
Infliximab | 3 (735) | 9 (738) |
4.1 (0.8–12.0) | 12.2 (5.6–23.2) | |
Certolizumab pegol | 3 (948) | 7 (962) |
3.2 (0.7–9.3) | 7.3 (2.9–15.0) | |
Golimumab | 0 (1104) | 5 (1119) |
0.0 (0.0–2.7) | 4.5 (1.5–10.4) | |
Tocilizumab | 1 (1008) | 5 (1030) |
1.0 (0.0-5.5) | 4.9 (1.6–11.3) | |
Rituximab | 4 (851) | 8 (830) |
4.7 (1.3–12.1) | 9.6 (4.2–19.0) | |
Abatacept | 2 (1775) | 7 (1767) |
1.1 (0.1–4.1) | 4.0 (1.6–8.2) |